• +1-646-491-9876
    • +91-20-67278686

    Search

    Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017

    Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689384
    • Category Healthcare
    • No. of Pages 50
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides an overview of the Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline landscape.

    Microscopic polyangiitis (MPA) is an uncommon disease. It is the result of blood vessel inflammation which can damage organ systems. The area most commonly affected by MPA includes the kidneys, lung, nerves, skin and joints. Symptoms include shortness of breath or cough, fever, loss of appetite, rashes, muscle and/or joint pain. Treatment includes immunosuppressive medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Microscopic Polyangiitis (MPA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III and Preclinical stages are 2, 3 and 2 respectively.

    Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA) (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Microscopic Polyangiitis (MPA) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Microscopic Polyangiitis (MPA) (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Microscopic Polyangiitis (MPA) (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Microscopic Polyangiitis (MPA) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Microscopic Polyangiitis (MPA) - Overview
    Microscopic Polyangiitis (MPA) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development
    Celltrion Inc
    ChemoCentryx Inc
    Coherus BioSciences Inc
    GlaxoSmithKline Plc
    Panacea Biotec Ltd
    Sandoz International GmbH
    Teijin Pharma Ltd
    Microscopic Polyangiitis (MPA) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Microscopic Polyangiitis (MPA) - Drug Profiles
    avacopan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Microscopic Polyangiitis (MPA) - Dormant Projects
    Microscopic Polyangiitis (MPA) - Product Development Milestones
    Featured News & Press Releases
    Dec 15, 2016: Celltrion Healthcare Hungary Receives CHMP Positive Opinion for Truxima
    Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis
    Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by Celltrion Inc, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by ChemoCentryx Inc, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by Coherus BioSciences Inc, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by Panacea Biotec Ltd, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by Sandoz International GmbH, H1 2017
    Microscopic Polyangiitis (MPA) - Pipeline by Teijin Pharma Ltd, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Microscopic Polyangiitis (MPA) - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Microscopic Polyangiitis (MPA), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Celltrion Inc
    ChemoCentryx Inc
    Coherus BioSciences Inc
    GlaxoSmithKline Plc
    Panacea Biotec Ltd
    Sandoz International GmbH
    Teijin Pharma Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-mpa-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-mpa-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//microscopic-polyangiitis-mpa-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments